Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Pandey S, Mangmool S, Madreiter-Sokolowski CT, Wichaiyo S, Luangmonkong T, Parichatikanond W (2023) Exendin-4 protects against high glucose-induced mitochondrial dysfunction and oxidative stress in SH-SY5Y neuroblastoma cells through GLP-1 receptor/Epac/Akt signaling
Frequency: Once every second or third day, depending on individual needs
[1] [6] Effectiveness appears promising in observational studies and case series
AOD-9604 was advanced through Phase I and Phase II clinical trials by Metabolic Pharmaceuticals between roughly 2003 and 2007 enrolling approximately 900 participants in total
US$ 27.24
US$ 27.58
US$ 24.22
US$ 25.22
US$ 23.20
US$ 20.58
